WASHINGTON (Reuters Health) Aug 14 – US healthcare officials are planning to reassess the benefits of combination hormone replacement therapies containing estrogen in response to a recent US government-sponsored study that revealed potentially serious side effects in postmenopausal women.
Performed as part of the government’s Women’s Health Initiative, the study was halted 3 years earlier than planned because of emerging evidence showing small yet statistically significant increases in the risk of heart disease, breast cancer, stroke and blood clots.
לסיכום יום העיון שנערך בישראל בנושא
מאמר המלא JAMA – ל
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!